Table 2.
Lupus and scleroderma disease presentation according to autoantibody serology, manifestations and tests
| Systemic Lupus Erythematosus (SLE) | Systemic Sclerosis (SSc) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| (n = 30) | (n = 30) | ||||||||
| Autoantibodies, manifestations and tests | SLEDAI score | Autoantibodies and manifestations | dcSSC(n = 14) | lcSSc(n = 5) | “other” (e.g. UCTD, morphea, Reynaud’s) (n = 3) | Unclassified(n = 7) | |||
| Mild, score <10(n = 21) | Moderate, score 10–20 (n = 3) | Severe, score >20 (n =0) | unscored (n = 6) | ANA positive (n = 22) 73 % | 13 | 6 | 5 | n/a | |
| ANA positive (n = 29) 97 % | 20 | 3 | 0 | 6 | ACA positive (n = 6) 20 % | 3 | 2 | 1 | n/a |
| DLE positive (n = 19) 63 % | 15 | 2 | 0 | 3 | ATA positive (n = 2) 7 % | 2 | 0 | 0 | n/a |
| Coombs’ test positive (n = 14) 47 % | 9 | 3 | 0 | 3 | ILD (n = 10) 33 % | 6 | 1 | 3 | n/a |
Abbreviations: ACA, anticentromere autoantibody; ANA, anti-nuclear antibodies; ATA, Antitopoisomerase antibodies; Coombs’ test, detects presence of antibodies that act against the surface of red blood cells, indicates haemolytic anaemia; DLE, Discoid lupus erythematosus; ILD, interstitial lung disease, indicator of direct pulmonary involvement, and leading cause of death; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; UCTD, undifferentiated connective tissue disease; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; n/a, results not available.